Effective October 12, 2022, CMS approve the use of four new CPT codes for the updated bivalent COVID-19 vaccine boosters and administration that were released by the AMA in August. The new codes and their descriptors are:
- CPT 91314: Moderna COVID-19 Vaccine, Bivalent Product
- Long descriptor: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use
- Short descriptor: SARSCOV2 VAC BVL 25MCG/.25ML
- CPT 0144A: Moderna COVID-19 Vaccine, Bivalent - Administration – Booster Dose
- Long descriptor: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, booster dose
- Short descriptor: ADM SRSCV2 BVL 25MCG/.25ML B
- CPT 91315: Pfizer-BioNTech COVID-19 Vaccine, Bivalent Product
- Long descriptor: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use
- Short descriptor: SARSCOV2 VAC BVL 10MCG/0.2ML
- CPT Code 0154A: Pfizer-BioNTech COVID-19 Vaccine, Bivalent - Administration – Booster Dose
- Long descriptor: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose
- Short descriptor: ADM SARSCV2 BVL 10MCG/.2ML B